Benzinga
Benzinga
Benzinga
venerdì, settembre 25

Prime Medicine Inc

PRMENASDAQ
Trade with Public
Trade with Public
$3.07
-0.06-1.92%
In chiusura: Sep 24, 5:00 PM EST
$3.43
0.3611.73%
Post-mercato: 7:59 PM EST
PRO
Perché si muove?:Prime Medicine shares are trading higher after the company announced the FD...
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Prime Medicine Financials

Prime Medicine (PRME) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from
Benzinga Newsdesk

PRO
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40) per share from the
Benzinga Newsdesk

PRO
Prime Medicine Expects That Its Cash, Cash Equivalents And Investments Of $213.3M As Of September 30, 2025 Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2027.

Benzinga Newsdesk

PRO
Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate

Benzinga Newsdesk

PRO
Prime Medicine Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $1.115M Beat $750.000K Estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 6.22 percent. This is a 10.87 percent increase over losses of $(0.46) per share from
Benzinga Newsdesk

PRO
Prime Medicine Q1 EPS $(0.40) Misses $(0.36) Estimate, Sales $1.45M Beat $1.05M Estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.36) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.44) per share from
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved